Efficacy and Safety of Q8003 in the Management of Post-bunionectomy Pain

A Placebo-controlled, Randomized, Double-blind Study of the Safety and Efficacy of Q8003 in the Management of Post-bunionectomy Pain

This study will explore the efficacy and safety of a fixed dose combination of morphine and oxycodone for management of acute postoperative pain. The study will explore the efficacy dose response and dosing interval required to maintain adequate analgesia at each tested dosage strength.

Study Overview

• Status: Completed
• Conditions: Postoperative Pain
• Intervention / Treatment: Drug: Placebo; Drug: Q8003 (morphine sulfate and oxycodone hydrochloride)

Detailed Description

This study is a randomized, double-blind, placebo-controlled, rising-dose/by-cohort study of the efficacy and safety of Q8003 in inpatients with acute pain following unilateral bunionectomy surgery. Patients in each dosing group will receive either Q8003 (approximately 50 per dosing group) or placebo (approximately 13 per dosing group), determined by random sequential assignment and blinded to patients and managing Investigators. Dosing groups will be enrolled sequentially in ascending order; only one dosing group will be open at a time for enrollment.

• Study Type: Interventional
• Enrollment (Actual): 256
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • California
    • Anaheim, California, United States, 92801
      • Advanced Clinical Research Institute
  • Maryland
    • Pasadena, Maryland, United States, 21122
      • Chesapeake Research Group
  • Pennsylvania
    • Altoona, Pennsylvania, United States, 16602
      • Advanced Regional Center for Foot and Ankle Care
  • Texas
    • Houston, Texas, United States, 77081
      • Scirex Research Center
  • Utah
    • Salt Lake City, Utah, United States, 84124
      • Jean Brown Research
    • Salt Lake City, Utah, United States, 84106
      • Lifetree Clinical Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patient is scheduled for bunionectomy surgery and is willing to stay in the study center for at least 48 hours from the initial dose of study medication post surgery.
• Females must be non-pregnant, non-lactating, and practicing an acceptable method of birth control, or be surgically sterile or postmenopausal (amenorrhea for ≥12 months).
• Patient has normal laboratory values or abnormal values judged not clinically significant by the Investigator for clinical chemistry and hematology (< 1.5 ULN).
• Patient is in general good health based on physical examination, medical history and clinically acceptable results for the following assessments: vital signs and a 12-lead electrocardiogram (ECG).
• Patient gives written informed consent and is able to understand the requirements of the study, adhere to the study restrictions, and be available for the required follow-up assessment.

Exclusion Criteria:

• Patient has a current acute or chronic disease that would interfere with evaluations of postoperative Q8003 efficacy or safety.
• Patient has a history of poor tolerance to short term opiate use in prior surgeries, based on patient self-report.
• Patient used opiates continuously (including tramadol) for more than five days in the past year.
• Patient has a history of pulmonary, cardiovascular, neurologic, endocrine, hepatic, gastrointestinal, or kidney disease or therapy that, in the opinion of the Investigator, would jeopardize the patient's well-being by participation in this study.
• Patient has positive HIV serology or signs of HIV infection or AIDS.
• Patient has positive HBsAg or HCV antibody.
• Patient is currently receiving any medications that are not at a stable dose (the same dose for >2 month prior to date of surgery).
• Patient is currently receiving muscle relaxants, antipsychotic drugs, monoamine oxidase inhibitors, or any medications for the treatment of depression.
• Patient has used systemic corticosteroids within previous fourteen (14) days.
• Patient was dosed with another investigational drug within 30 days prior to the Screening Visit.
• Patient has current evidence of alcohol abuse (regularly drinks more than 4 units of alcohol per day; 1 unit = ½ pint of beer, 1 glass of wine, or 1 ounce of spirit).
• Patient has a history of abusing licit or illicit drug substances within five (5) years of study entry.
• Patient is obese with a body mass index >32.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1	Drug: Q8003 (morphine sulfate and oxycodone hydrochloride); Capsules, four different mg dosage strengths
Placebo Comparator: 2	Drug: Placebo; Capsules

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Difference in pain intensity scores from baseline	48 hours

Secondary Outcome Measures

Outcome Measure	Time Frame
Appropriate dosing interval for each tested dose level	48 hours
Safety: incidence of opioid-related adverse events	48 hours

Collaborators and Investigators

• Sponsor: QRxPharma Inc.
• Investigators: Study Director: Warren Stern, Ph.D., QRxPharma Inc.

Study record dates

Study Major Dates

• Study Start: November 1, 2007
• Primary Completion (Actual): April 1, 2008
• Study Completion (Actual): April 1, 2008

Study Registration Dates

• First Submitted: November 14, 2007
• First Submitted That Met QC Criteria: November 15, 2007
• First Posted (Estimate): November 19, 2007

Study Record Updates

• Last Update Posted (Estimate): May 17, 2012
• Last Update Submitted That Met QC Criteria: May 15, 2012
• Last Verified: May 1, 2012

More Information

Terms related to this study

• Keywords: Acute; Bunionectomy
• Additional Relevant MeSH Terms: Pathologic Processes; Postoperative Complications; Pain; Neurologic Manifestations; Pain, Postoperative; Physiological Effects of Drugs; Central Nervous System Depressants; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Analgesics, Opioid; Narcotics; Morphine; Oxycodone
• Other Study ID Numbers: Q8003-007